

REMARKS

In response to the Restriction Requirement mailed September 24, 2003, applicants elect Groups 16-30, claims 5-14, and more specifically Group 11, drawn to the isolated nucleic acid of SEQ ID NO: 21 encoding the polypeptide of SEQ ID NO: 22; and vector and cell comprising said nucleic acid encoding the polypeptide, classified in class 435, subclass 320.1, without traverse.


Claims 1-4 and 15-49 have been canceled without prejudice or disclaimer as drawn to non-elected subject matter. Applicant reserves the right to pursue these claims in a later application. Elected claims 9 and 12 have been amended, and elected claims 5-8, 10, and 11 have been canceled and replaced with new claims 50-54 herein. Support for new claims 50-54 can be found in originally filed claims 1-49 and throughout the specification (for example, claims 5-14, and page 28, line 36 through page 29, line 3). Upon entry of this amendment, claims 9, 12-14, and 50-54 will be pending. No new matter has been added.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Dated: November 24, 2003

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623